PCSK9 inhibitors are used for high-risk patients (for secondary prevention or severe primary hypercholesterolemia) who have statin intolerance syndrome or who have an insufficient reduction in LDL-C level while taking the maximum tolerated dose of a statin plus ezetimibe [8]. This evidence concerns the gene PCSK9 and Hypercholesterolemia.